Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2003 Aug;14(8):3082–3096. doi: 10.1091/mbc.E02-10-0631

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2003, The American Society for Cell Biology

PMC Copyright notice

Figure 7. — cybL-deficient cells are specifically resistant to cytostatic drug-induced apoptosis. (A) Comparison of apoptosis in cells lacking cybL or reconstituted with cybL. CybL-deficient (CybL –/–) as well as cells that express a cybL construct (CybL-GFP) were treated with the indicated cytostatic drugs for 18 h after which the extent of apoptosis was quantified by FACS analysis. The means and the SD of three independent measurements are given. The right hand panel shows the comparison of the percentage of apoptosis reduction between complex II-deficient versus -reconstituted cells. The means of the apoptosis inductions for each inducer (minus control) were put in relation and its percentage was subtracted from 100%. (B) Comparison of the apoptosis potential of cells with and without an intact respiratory chain. HeLa and HeLa ρ0 cells were incubated with the same drugs used in (A) and apoptosis was quantified by FACS. The right panel states the percentage of apoptosis reduction between HeLa ρ0 versus WT HeLa cells that was calculated as in A.